Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Nov. 22, 2023	Sumitomo Pharma Announces the Approval of XENLETA (lefamulin acetate) for the Treatment of Community-Acquired Pneumonia in China	Products
Nov. 20, 2023	Sumitomo Pharma and ORIX Eco Services to Collaborate on Recycling Blister Packaging Waste at Suzuka Plant	Sustainability
Nov. 10, 2023	Sumitomo Pharma Receives SBTi (Science Based Targets initiative) Approval	Sustainability
Nov. 06, 2023	Posted Video of Conference on Q2 FY2023 Financial Results [Webcast]	Finances
Nov. 06, 2023	Sumitomo Pharma America to Present Preliminary Clinical Data Evaluating Investigational Oncology Agents TP-3654 and DSP-5336 at the American Society of Hematology Annual Meeting（PDF/169KB）	R&D
Oct. 31, 2023	Presentation Material (Conference on Q2 FY2023 Financial Results)（PDF/514KB）	Finances

Jan. 31, 2024	3rd Quarter of FY2023 financial results announcement (planned, 3:30 p.m.)